Table 1 Baseline characteristics of patients initiating biologic therapy, categorised by disease type
Characteristic | All patients | Crohn’s disease | Ulcerative colitis |
|---|---|---|---|
Total number, n (%) | 240 | 153 (63.8) | 87 (36.3) |
Sex | |||
 Male | 128 (53.3) | 81 (52.9) | 47 (54) |
 Female | 112 (46.7) | 72 (47.1) | 40 (46) |
Age at referral, in years | |||
 Median (IQR) | 43 (35–36) | 41.1 (34.2–55.1) | 44.4 (35–58.4) |
 ≤ 60 | 190 (79.2) | 125 (81.7) | 65 (74.7) |
 > 60 | 50 (20.8) | 28 (18.3) | 22 (25.3) |
Comorbid status [CCI] | |||
 0 | 147 (61.3) | 97 (63.4) | 50 (57.5) |
 ≥ 1 | 93 (38.8) | 56 (36.6) | 37 (42.5) |
Ethnicity | |||
 White British | 91 (37.9) | 68 (44.4) | 23 (26.4) |
 Asian Indian or Pakistani | 88 (36.7) | 47 (30.7) | 41 (47.1) |
 Other ethnic groupa | 61 (25.4) | 38 (24.8) | 23 (26.4) |
Index of Multiple Deprivation Decile [IMDD] | |||
 ≤ 5 | 102 (42.5) | 67 (43.8) | 35 (40.2) |
 > 5 | 138 (57.5) | 86 (56.2) | 52 (59.8) |
 Mean (SD) | 7.5 (2.1) | 6 (2.3) | 6.3 (2.4) |
Age at diagnosis, years | |||
 Median (IQR) | 29 (20–41) | 26 (19–39) | 33 (24.5–45.5) |
 ≤ 60 | 222 (92.5) | 143 (93.5) | 79 (90.8) |
 > 60 | 18 (7.5) | 10 (6.5) | 8 (9.2) |
Disease duration, years | |||
 ≤ 2 | 44 (18.3) | 28 (18.3) | 16 (18.4) |
 Diagnosed within 6 months | 13 (5.4) | 12 (7.8) | 1 (1.1) |
 > 2 to 10 years | 90 (37.5) | 53 (34.6) | 37 (42.5) |
 > 10 years | 106 (44.2) | 72 (47.1) | 34 (39.1) |
Disease location for CD [Montreal classification] | |||
 L1 |  34 (14.2) | 34 (22.2) |  |
 L2 |  37 (15.4) | 37 (24.2) |  |
 L3 |  80 (33.3) | 80 (52.3) |  |
 L4 ( +) |  7 (2.9) | 7 (4.6) |  |
Disease behaviour for CD [Montreal classification] | |||
 B1 |  105 (43.8) | 105 (68.6) |  |
 B2 |  30 (12.5) | 30 (19.6) |  |
 B3 |  18 (7.5) | 18 (11.8) |  |
Perianal CD | |||
 Yes |  37 (15.4) | 37 (24.2) |  |
Disease extent for UC [Montreal classification] | |||
 E1 | 6 (2.5) |  | 6 (1.1) |
 E2 | 37 (15.4) |  | 37 (42.5) |
 E3 | 44 (18.3) |  | 44 (50.6) |
Previous CD surgery | |||
 Yes |  56 (23.3) | 56 (36.6) |  |
C-reactive protein (CRP), mg/L | |||
 Total number, n (%) | 233 (97.1) | 148 (96.7) | 85 (97.7) |
 Median (IQR) | 6.2 (1.8–20.2) | 8.5 (2.4–29.7) | 3.5 (1.0–9.9) |
Faecal calprotectin, ug/g | |||
 Total number, n (%) | 154 (64.2) | 95 (62.1) | 59 (67.8) |
 Median (IQR) | 470 (166–993) | 423 (158–962) | 555 (174–1070) |
Concomitant oral steroids | |||
 At the time of referral, n (%) | 68 (28.3) | 33 (21.6) | 35 (40.2) |
 At the time of BC, n (%) | 51 (21.3) | 22 (14.4) | 29 (33.3) |
Immunomodulator naïve | |||
 Yes | 94 (39.2) | 25 (16.3) | 69 (79.3) |
Biologic naïve | |||
 Yes | 141 (58.8) | 87 (56.9) | 54 (62.1) |